Alectinib (Alecensa)

DRUG3 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Advanced MalignanciesAnaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

Phase 3

An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)

Active, not recruitingCTIS2023-506184-34-00

F. Hoffmann-La Roche AGAdvanced Malignancies

Start: 2019-08-09Target: 104Updated: 2025-11-10

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

CompletedCTIS2023-506859-13-00

F. Hoffmann-La Roche AGAnaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Start: 2014-09-09End: 2025-03-14Target: 51Updated: 2025-04-22

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients with Resectable Stage I-III Non-Small Cell Lung Cancer, selected according to Biomarker Status

RecruitingCTIS2024-511239-91-00

F. Hoffmann-La Roche AGResectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

Start: 2025-05-05Target: 54Updated: 2025-11-10